Related Experiment Video
Updated: Jun 29, 2025
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Structural Analysis of the Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase
Tyler S Beyett1,2, Jaimin K Rana1,2, Ilse K Schaeffner1,2
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA, 450 Brookline Avenue, LC4313.
Abstract:
A novel macrocyclic inhibitor of mutant EGFR (BI-4020) has shown promise in pre-clinical studies of T790M and C797S drug-resistant non-small cell lung cancer. To better understand the molecular basis for BI-4020 selectivity and potency, we have carried out biochemical activity assays and structural analysis with X-ray crystallography. Biochemical potencies agree with previous studies indicating that BI-4020 is uniquely potent against drug-resistant L858R/T790M and L858R/T790M/C797S variants. X-ray structures with wild-type (2.4 Å) and T790M/V948R (3.1 Å) EGFR kinase domains show that BI-4020 is likely rendered selective due to interactions with the kinase domain hinge region as well as T790M, akin to Osimertinib. Additionally, BI-4020 is also rendered more potent due to its constrained macrocycle geometry as well as additional H-bonds to conserved K745 and T845 residues in both active and inactive conformations. These findings taken together show how this novel macrocyclic inhibitor is both highly potent and selective for mutant EGFR in a reversible mechanism and motivate structure-inspired approaches to developing targeted therapies in medicinal oncology.
Insights
A new macrocyclic inhibitor, BI-4020, shows high potency and selectivity against drug-resistant mutant EGFR, offering a promising avenue for targeted non-small cell lung cancer therapy.
Area of Science:
- Medicinal Chemistry
- Molecular Biology
- Oncology
Background:
- Non-small cell lung cancer (NSCLC) often develops resistance to targeted therapies.
- Mutations in the epidermal growth factor receptor (EGFR), such as T790M and C797S, are key drivers of resistance.
- Novel inhibitors are needed to overcome these resistance mechanisms.
Purpose of the Study:
- To elucidate the molecular basis for the selectivity and potency of the novel macrocyclic inhibitor BI-4020.
- To understand its interaction with wild-type and mutant EGFR variants.
- To provide insights for the development of next-generation EGFR inhibitors.
Main Methods:
- Biochemical activity assays were performed to determine inhibitor potency.
- X-ray crystallography was used to analyze the structural interactions of BI-4020 with EGFR kinase domains.
- Comparative analysis with existing inhibitors like Osimertinib was conducted.
Main Results:
- BI-4020 demonstrated unique potency against drug-resistant EGFR variants (L858R/T790M and L858R/T790M/C797S).
- Structural analysis revealed that BI-4020 interacts with the EGFR hinge region and T790M mutation, contributing to selectivity.
- The inhibitor's constrained macrocycle and additional hydrogen bonds enhance potency against both active and inactive EGFR conformations.
Conclusions:
- BI-4020 is a highly potent and selective reversible inhibitor of mutant EGFR.
- Its unique binding mode provides a foundation for structure-inspired design of targeted therapies for NSCLC.
- These findings support the development of novel medicinal oncology strategies against drug-resistant cancers.
More Related Videos
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
Published on: September 11, 2015
